Malaria, leishmaniasis, Chagas disease, and human African trypanosomiasis continue to
cause considerable suffering and death in developing countries. Current treatment options …

Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp.,
Entamoeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are …

Pteridine reductase (PTR1) is essential for salvage of pterins by parasitic trypanosomatids
and is a target for the development of improved therapies. To identify inhibitors of …

A molecular docking analysis has been carried out to examine potential Leishmania protein
targets of antiprotozoal plant-derived polyphenolic compounds. A total of 352 phenolic …

In this paper, the design, synthesis and biological evaluation of a set of quinazoline-2, 4, 6-
triamine derivatives (1–9) as trypanocidal, antileishmanial and antiplasmodial agents are …

Folate analogue inhibitors of Leishmania major pteridine reductase (PTR1) are potential
antiparasitic drug candidates for combined therapy with dihydrofolate reductase (DHFR) …

Neglected Tropical Diseases (NTDs), like leishmaniasis, are major causes of mortality in
resource-limited countries. The mortality associated with these diseases is largely due to …

Leishmaniasis is a neglected tropical disease of major public health concern. Challenges
with current therapeutics have led to the exploration of plant medicine for potential …

Background/Objectives: Pteridine reductase 1 (PTR1) has been one of the prime targets for
discovering novel antileishmanial therapeutics in the fight against Leishmaniasis. This …

A series of thiazolopyrimidine derivatives was designed and synthesized as a Leishmania
major pteridine reductase 1 (LmPTR1) enzyme inhibitor. Their LmPTR1 inhibitor activities …